Drug development consultancy, NDA Group, has appointed Alison McGregor as its principal consultant following the opening of its new US office in San Francisco.
McGregor joins the group from BioMarin Pharmaceuticals, where she was previously global regulatory affairs leader.
She has over 20 years’ experience in the pharmaceutical sector working for both industry and regulatory agencies including AstraZeneca and the UK’s MHRA.
Johan Stromquist, chief executive officer, NDA Group, said: “The US expansion is our main focus in 2018 and we are planning expanding our support for FDA and EMA submissions, milestone meetings and de-risking early stage data packages.
“Bringing Alison on-board is particularly important as her experience represents the ideal we share across NDA – that of bringing diverse regulatory requirements together to create the best possible development programmes as efficiently as possible.”